Share This

PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations
CASTRES, France , June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ...
2024-06-05T    Health Care/Hospital   Medical/Pharmaceuticals 
GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024
YONGIN, South Korea , June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, presented new data from its AI-based liquid biopsy platform for non-invasive colorectal ...
2024-06-05T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ASG Pioneers Development of novel inhaled drugs and Accelerates R&D Progress
TAIPEI , June 5, 2024 /PRNewswire/ – Asia Scientific Global (ASG), a leader in the research and development of novel inhaled drugs, has set up a laboratory in Taiwan , and plans to establish a second ...
2024-06-05T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
SUZHOU, China and ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis ...
2024-06-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM
SUZHOU, China , and ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis ...
2024-06-05T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Dalton Pharma Services Invests in Robotic Aseptic Powder Fill-Finish Line from 3P innovation
TORONTO , June 5, 2024 /PRNewswire/ -- Pharmaceutical manufacturing company, Dalton Pharma Services  (a Seikagaku Group company ), has recently commissioned 3P innovation  ( Warwick, ...
2024-06-05T    Health Care/Hospital   Medical/Pharmaceuticals 
RestoringVision Awarded $4 Million Grant to Restore Sight to 2.5 Million People with Presbyopia in India and Nigeria
SAN FRANCISCO , June 4, 2024 /PRNewswire/ -- RestoringVision has been awarded a $4 million grant from Founders Pledge to address presbyopia at scale in India and Nigeria . This investment will ...
2024-06-04T    Health Care/Hospital   Medical/Pharmaceuticals 
Zymo Research Unveils PureRec DSN: The Most Selective Duplex-Specific Nuclease
IRVINE, Calif. , June 4, 2024 /PRNewswire/ -- Zymo Research, a leader in biotechnological advancement has launched a new nuclease called PureRec Duplex-Specific Nuclease (DSN) that selectively digests ...
2024-06-04T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO
SHANGHAI , June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies ...
2024-06-04T    Health Care/Hospital   Medical/Pharmaceuticals 
Masdar City to Showcase Its Life Sciences Hub at BIO24 in San Diego
Masdar City to showcase why they are the leading destination for the life sciences sector at BIO24 ...
2024-06-04T    Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals   Real Estate 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.